# Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma

## TL;DR

This paper reviews recent advances in the medical treatment of malignant pleural mesothelioma, focusing on new therapies that improve patient outcomes.

## Contribution

The paper highlights the progress of dual immune checkpoint inhibitors and emerging targeted and cell-based therapies for mesothelioma.

## Key findings

- Dual immune checkpoint inhibitors have significantly improved survival outcomes in mesothelioma patients.
- Targeted therapies based on molecular biology offer potential for personalized treatment approaches.
- New strategies like cell therapy and oncolytic virus therapy show emerging promise in clinical trials.

## Abstract

恶性胸膜间皮瘤（malignant pleural mesothelioma, MPM）是一种源自胸膜间皮细胞的高度侵袭性恶性肿瘤，主要与石棉暴露相关，且预后通常较差。由于该病早期缺乏特异性临床表现，诊断具有一定挑战性，导致多数患者确诊时已处于晚期，从而限制了外科手术治疗的效果，因此需要依赖全身治疗。尽管培美曲塞联合铂类化疗仍为不可切除MPM的一线标准治疗方案，但其疗效有限，亟需更有效的治疗策略。近年来，双免疫检查点抑制剂在MPM治疗中取得了重要进展，显著改善了患者的生存预后。随着对MPM分子生物学研究的深入，靶向治疗为患者提供了潜在的个性化治疗选择。此外，细胞治疗、溶瘤病毒疗法等新型治疗策略的治疗潜力已开始显现。本文综述了MPM的最新内科治疗进展，并对未来治疗方向进行展望，以期为临床实践提供参考。

Summary of key clinical trial designs and outcomes in the field of MPM treatment